A citation-based method for searching scientific literature

Laurie H Sehn, Gilles Salles. N Engl J Med 2021
Times Cited: 88







List of co-cited articles
359 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Christian Récher, Bertrand Coiffier, Corinne Haioun, Thierry Jo Molina, Christophe Fermé, Olivier Casasnovas, Catherine Thiéblemont, André Bosly, Guy Laurent, Franck Morschhauser,[...]. Lancet 2011
242
3

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
Peter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, Oliver W Press, Thomas M Habermann, Julie M Vose, Martin Bast, Ranjana H Advani, Robert Tibshirani, Andrew M Evens,[...]. Br J Haematol 2014
55
5

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Deborah M Stephens, Hongli Li, Michael L LeBlanc, Soham D Puvvada, Daniel Persky, Jonathan W Friedberg, Sonali M Smith. J Clin Oncol 2016
64
4

Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
David Hui, Bradley Proctor, Jane Donaldson, Tamara Shenkier, Paul Hoskins, Richard Klasa, Kerry Savage, Mukesh Chhanabhai, Randy D Gascoyne, Joseph M Connors,[...]. Leuk Lymphoma 2010
33
9

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
Pallawi Torka, Shalin K Kothari, Suchitra Sundaram, Shaoying Li, L Jeffrey Medeiros, Emily C Ayers, Daniel J Landsburg, David A Bond, Kami J Maddocks, Anshu Giri,[...]. Blood Adv 2020
19
15

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
C Y Cheah, K E Herbert, K O'Rourke, G A Kennedy, A George, P L Fedele, M Gilbertson, S Y Tan, D S Ritchie, S S Opat,[...]. Br J Cancer 2014
81
3

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip C Caron, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Anita Kumar,[...]. Blood Cancer J 2021
11
27

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj,[...]. Lancet Oncol 2020
124
3

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Wojciech J Jurczak, Ian W Flinn, Christopher R Flowers, Peter Martin, Andreas Viardot,[...]. N Engl J Med 2014
752
3

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Yucai Wang, Umar Farooq, Brian K Link, Melissa C Larson, Rebecca L King, Matthew J Maurer, Cristine Allmer, Mehrdad Hefazi, Carrie A Thompson, Ivana N Micallef,[...]. J Clin Oncol 2019
25
12

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.
Patrick J Stiff, Joseph M Unger, James R Cook, Louis S Constine, Stephen Couban, Douglas A Stewart, Thomas C Shea, Pierluigi Porcu, Jane N Winter, Brad S Kahl,[...]. N Engl J Med 2013
222
3

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Laurie H Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam, Umberto Vitolo. J Hematol Oncol 2020
42
7

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Marcelo C Pasquini, Zhen-Huan Hu, Kevin Curran, Theodore Laetsch, Frederick Locke, Rayne Rouce, Michael A Pulsipher, Christine L Phillips, Amy Keating, Matthew J Frigault,[...]. Blood Adv 2020
116
3

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
3

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz, Gilles Salles, Pashna N Munshi, Carla Casulo, David G Maloney, Sven de Vos,[...]. Lancet Oncol 2022
21
14

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, Bruce Woda, Richard I Fisher, Bruce A Peterson,[...]. J Clin Oncol 2006
3

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Mathias Haenel, Peter Borchmann, Christian Schmidt, Andreas Viardot, Martin Bentz, Norma Peter, Gerhard Ehninger,[...]. Lancet Oncol 2012
169
3

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Hervé Tilly, Franck Morschhauser, Laurie H Sehn, Jonathan W Friedberg, Marek Trněný, Jeff P Sharman, Charles Herbaux, John M Burke, Matthew Matasar, Shinya Rai,[...]. N Engl J Med 2022
21
14

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Joost S Vermaat, Sebastiaan F Somers, Liesbeth C de Wreede, Willem Kraan, Ruben A L de Groen, Anne M R Schrader, Emile D Kerver, Cornelis G Scheepstra, Henriëtte Berenschot, Wendy Deenik,[...]. Haematologica 2020
30
6

CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Colm Keane, Devinder Gill, Frank Vari, Donna Cross, Lynn Griffiths, Maher Gandhi. Am J Hematol 2013
57
3

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, Miguel A Piris, Alison H Banham, Jan Delabie, Rita M Braziel, Huimin Geng, Javeed Iqbal, Georg Lenz,[...]. Clin Cancer Res 2009
467
2

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
N L Harris, E S Jaffe, H Stein, P M Banks, J K Chan, M L Cleary, G Delsol, C De Wolf-Peeters, B Falini, K C Gatter. Blood 1994
2

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
Ash A Alizadeh, Andrew J Gentles, Alvaro J Alencar, Chih Long Liu, Holbrook E Kohrt, Roch Houot, Matthew J Goldstein, Shuchun Zhao, Yasodha Natkunam, Ranjana H Advani,[...]. Blood 2011
145
2

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
David W Scott, George W Wright, P Mickey Williams, Chih-Jian Lih, William Walsh, Elaine S Jaffe, Andreas Rosenwald, Elias Campo, Wing C Chan, Joseph M Connors,[...]. Blood 2014
382
2

A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas.
Claudio Tripodo, Federica Zanardi, Fabio Iannelli, Saveria Mazzara, Mariella Vegliante, Gaia Morello, Arianna Di Napoli, Alessandro Mangogna, Fabio Facchetti, Sabina Sangaletti,[...]. iScience 2020
14
14

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N Meyer, Kai Fu, Timothy C Greiner, Lynette M Smith, Jan Delabie, Randy D Gascoyne, German Ott, Andreas Rosenwald, Rita M Braziel, Elias Campo,[...]. J Clin Oncol 2011
341
2

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef,[...]. J Clin Oncol 2015
272
2


Hiv and Lymphoma: from Epidemiology to Clinical Management.
Alessandro Re, Chiara Cattaneo, Giuseppe Rossi. Mediterr J Hematol Infect Dis 2019
32
6

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Anna H Turaj, Kerry L Cox, Christine A Penfold, Ruth R French, C Ian Mockridge, Jane E Willoughby, Alison L Tutt, Jordana Griffiths, Peter W M Johnson, Martin J Glennie,[...]. Sci Rep 2018
16
12

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Idit Sagiv-Barfi, Holbrook E Kohrt, Laura Burckhardt, Debra K Czerwinski, Ronald Levy. Blood 2015
57
3

Influence of tumour micro-environment heterogeneity on therapeutic response.
Melissa R Junttila, Frederic J de Sauvage. Nature 2013
2

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T McCabe, Heidi M Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S Van Aller, Yan Liu, Alan P Graves, Anthony Della Pietra, Elsie Diaz,[...]. Nature 2012
2

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Mara Compagno, Wei Keat Lim, Adina Grunn, Subhadra V Nandula, Manisha Brahmachary, Qiong Shen, Francesco Bertoni, Maurilio Ponzoni, Marta Scandurra, Andrea Califano,[...]. Nature 2009
762
2


Oncogenically active MYD88 mutations in human lymphoma.
Vu N Ngo, Ryan M Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao, Kian-Huat Lim, Holger Kohlhammer, Weihong Xu, Yandan Yang, Hong Zhao,[...]. Nature 2011
997
2

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Ling-Hua Zhang, Jolanta Kosek, Maria Wang, Carla Heise, Peter H Schafer, Rajesh Chopra. Br J Haematol 2013
117
2

Spherical cancer models in tumor biology.
Louis-Bastien Weiswald, Dominique Bellet, Virginie Dangles-Marie. Neoplasia 2015
624
2

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Kamil Bojarczuk, Kirsty Wienand, Jeremy A Ryan, Linfeng Chen, Mariana Villalobos-Ortiz, Elisa Mandato, Joanna Stachura, Anthony Letai, Lee N Lawton, Bjoern Chapuy,[...]. Blood 2019
50
4

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Ryan D Morin, Maria Mendez-Lago, Andrew J Mungall, Rodrigo Goya, Karen L Mungall, Richard D Corbett, Nathalie A Johnson, Tesa M Severson, Readman Chiu, Matthew Field,[...]. Nature 2011
2

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.
Milena Sant, Claudia Allemani, Carmen Tereanu, Roberta De Angelis, Riccardo Capocaccia, Otto Visser, Rafael Marcos-Gragera, Marc Maynadié, Arianna Simonetti, Jean-Michel Lutz,[...]. Blood 2010
527
2

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Lorena Fontan, Rebecca Goldstein, Gabriella Casalena, Matthew Durant, Matthew R Teater, Jimmy Wilson, Jude Phillip, Min Xia, Shivem Shah, Ilkay Us,[...]. Blood 2021
9
22

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Jens G Lohr, Petar Stojanov, Michael S Lawrence, Daniel Auclair, Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, Birgit Knoechel, Yan W Asmann, Susan L Slager,[...]. Proc Natl Acad Sci U S A 2012
693
2

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, Matthew D Ducar, Yuxiang Tan, Linfeng Chen, Margaretha G M Roemer, Jing Ouyang, Amanda L Christie, Liye Zhang,[...]. Blood 2016
50
4

HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Siyu Deng, Qianwen Hu, Heng Zhang, Fang Yang, Cheng Peng, Chuanxin Huang. Mol Cancer Ther 2019
45
4


Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Jiyuan Zhang, David Dominguez-Sola, Shafinaz Hussein, Ji-Eun Lee, Antony B Holmes, Mukesh Bansal, Sofija Vlasevska, Tongwei Mo, Hongyan Tang, Katia Basso,[...]. Nat Med 2015
248
2

Germinal centres and B cell lymphomagenesis.
Katia Basso, Riccardo Dalla-Favera. Nat Rev Immunol 2015
264
2

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Weiping Li, Shiv K Gupta, Weiguo Han, Ryan A Kundson, Sara Nelson, Darlene Knutson, Patricia T Greipp, Sherine F Elsawa, Eduardo M Sotomayor, Mamta Gupta. J Hematol Oncol 2019
35
5

Extracellular Vesicles: New Players in Lymphomas.
Victor Navarro-Tableros, Yonathan Gomez, Giovanni Camussi, Maria Felice Brizzi. Int J Mol Sci 2018
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.